Coherus’s key strengths include a successful pivot to a focused oncology identity, an approved and differentiated PD-1 inhibitor in a niche indication, and clear progress in restoring profitability and improving margins. The company has meaningfully reduced operating expenses, improved gross economics, paid down a sizable portion of its debt, and stabilized its cash position. Its innovation strategy, centered on tumor microenvironment–targeting antibodies combined with LOQTORZI, offers a coherent and potentially scalable growth platform if clinical results are favorable.

Major risks stem from a weakened balance sheet with negative equity, slimmer liquidity, and a history of cash burn that has not yet fully reversed. Operationally, the company is still not generating positive operating or free cash flow and remains reliant on a narrow set of products and pipeline assets in a fiercely competitive oncology market. Clinical and regulatory setbacks, slower-than-expected uptake of LOQTORZI, pricing pressure, or the need for future capital raises could all challenge the sustainability of the current strategy.

The outlook for Coherus is that of a high-risk, high-uncertainty turnaround in progress. Financial trends are moving in the right direction—better margins, lower debt, and smaller cash losses—while the strategic focus on immuno-oncology provides a clear narrative for potential future growth. At the same time, the company still needs to prove that its new business model can consistently generate cash, strengthen the balance sheet, and expand its oncology franchise in the face of well-capitalized competitors. Future performance will hinge on the commercial trajectory of LOQTORZI, the success of key pipeline programs, and disciplined financial management over the next several years.